Parkinson disease (PD) is the most common movement disorder affecting over one million people in North America alone and results in an insidious reduction in the quality of life and ability to function. A hallmark of PD is the brain accumulation of neuronal cytoplasmic inclusions comprised of the protein alpha synuclein, but the presence of alpha synuclein brain aggregates is observed in a spectrum of neurodegenerative diseases, including dementia with Lewy body. Several findings suggest that alpha synuclein amyloid pathology may spread during disease progression by a self-templating alteration in protein conformation mechanism, however other alternative and/or synergistic biological mechanisms, as supported by our data, could also lead to progression of alpha synuclein pathology. From a therapeutic aspect it is critical to determine the relative importance, mechanisms and physiological consequences of the spread of alpha synuclein aggregation in disease. It this proposal, two major specific aims are proposed to inform on alpha synuclein induced and spread of disease: 1) Using both wild-type and disease causing mutant forms of alpha synuclein with unique aggregation properties, we will directly investigated that alpha synuclein aggregation can spread within the central nervous system and from the periphery with specific conformational characteristics. 2) We will assess the importance of alternative biological mechanisms including perturbation of the protein network homeostasis, neuronal intermediate filament integrity, neurotoxicity and age-related changes in the induction and propagation of alpha synuclein pathology by exogenous alpha synuclein challenges. These studies will provide critical insights on the mechanisms and the involvement of alpha synuclein aggregation in PD disease progression with the objective of guiding the development of novel therapeutics.
Parkinson disease is an insidious neurodegenerative disease, affecting ~1% of the population over 65 years of age. Progressive aggregation and inclusion formation of the protein alpha synuclein is a hallmark of this disorder and the planned research project focuses on understanding the underlying biological and molecular mechanisms involved in the development of disease with the objective of guiding novel therapeutic interventions.
|Pace, Michael C; Xu, Guilian; Fromholt, Susan et al. (2018) Changes in proteome solubility indicate widespread proteostatic disruption in mouse models of neurodegenerative disease. Acta Neuropathol 136:919-938|
|Croft, Cara L; Moore, Brenda D; Ran, Yong et al. (2018) Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. PLoS One 13:e0195211|
|Strang, Kevin H; Croft, Cara L; Sorrentino, Zachary A et al. (2018) Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies. J Biol Chem 293:2408-2421|
|Sorrentino, Zachary A; Xia, Yuxing; Funk, Cory et al. (2018) Motor neuron loss and neuroinflammation in a model of ?-synuclein-induced neurodegeneration. Neurobiol Dis 120:98-106|
|Ayers, Jacob I; Riffe, Cara J; Sorrentino, Zachary A et al. (2018) Localized Induction of Wild-Type and Mutant Alpha-Synuclein Aggregation Reveals Propagation along Neuroanatomical Tracts. J Virol 92:|
|Phan, Hanh T M; Bartz, Jason C; Ayers, Jacob et al. (2018) Adsorption and decontamination of ?-synuclein from medically and environmentally-relevant surfaces. Colloids Surf B Biointerfaces 166:98-107|
|Strang, Kevin H; Sorrentino, Zachary A; Riffe, Cara J et al. (2018) Phosphorylation of serine 305 in tau inhibits aggregation. Neurosci Lett 692:187-192|
|Pace, Michael C; Xu, Guilian; Fromholt, Susan et al. (2018) Differential induction of mutant SOD1 misfolding and aggregation by tau and ?-synuclein pathology. Mol Neurodegener 13:23|
|Giraldo, Genesys; Brooks, Mieu; Giasson, Benoit I et al. (2018) Locomotor differences in mice expressing wild-type human ?-synuclein. Neurobiol Aging 65:140-148|
|Rutherford, Nicola J; Brooks, Mieu; Riffe, Cara J et al. (2017) Prion-like transmission of ?-synuclein pathology in the context of an NFL null background. Neurosci Lett 661:114-120|
Showing the most recent 10 out of 24 publications